C1 Esterase Inhibitor
Brand name: Haegarda
Rank #267 of 500 drugs by total cost
$45.8M
Total Cost
894
Total Claims
$45.8M
Total Cost
46
Prescribers
$51K
Cost per Claim
0
Beneficiaries
894
30-Day Fills
$995K
Avg Cost/Provider
19
Avg Claims/Provider
About C1 Esterase Inhibitor
C1 Esterase Inhibitor (sold as Haegarda) was prescribed 894 times by 46 Medicare Part D providers in 2023, costing the program $45.8M. At $51K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 264 | Glipizide (Glipizide) | $46.9M | 2,961,035 |
| 265 | Losartan/Hydrochlorothiazide (Losartan-Hydrochlorothiazide) | $46.3M | 2,039,676 |
| 266 | Darunavir (Prezista) | $46.0M | 21,793 |
| 267 | C1 Esterase Inhibitor (Haegarda) | $45.8M | 894 |
| 268 | Alectinib Hcl (Alecensa) | $45.7M | 2,686 |
| 269 | Ipratropium Bromide (Ipratropium Bromide) | $45.4M | 656,249 |
| 270 | Amantadine Hcl (Amantadine) | $45.2M | 173,840 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology